Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus

Published:2021-01-13 Issue:6 Volume:10 Page:660-668
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Wu Min¹,Li Qian‐Qian¹,Zhang Hong¹,Zhu Xiao‐Xue¹,Li Xiao‐Jiao¹,Li Ying²,Sun Hai‐Gang²,Ding Yan‐Hua¹

Affiliation:

1. Department of Phase I Clinical Trial Unit First Hospital of Jilin University Changchun Jilin China

2. Shenzhen Salubris Pharmaceuticals Co., Ltd. Shenzhen Guangdong China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.895

Reference27 articles.

1. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

2. The Physiology of Incretin Hormones and the Basis for DPP-4 Inhibitors

3. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

4. Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man

5. Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM);European Journal of Medicinal Chemistry;2024-06

2. Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial;BMC Medicine;2023-10-09

3. Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants;Journal of Medicinal Chemistry;2023-08-30

4. Gender representation in drug development studies for diabetes mellitus. A systematic review;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-08